Discover
DFTX
Definium Therapeutics, Inc.
36.90
2 x 24.69
2 x 42.11
bid
ask
+
2.72
7.96%
2 @ 07:04 PM
37.40 +0.50 (1.36%)
| Ytd | 175.58% | |
| 1y | 195.20% |
34.57
day range
38.04
10.68
52 week range
48.45
| Open | 34.85 | Prev Close | 34.18 | Low | 34.57 | High | 38.04 | Mkt Cap | 4.96B |
| Vol | 2.77M | Avg Vol | 2.13M | EPS | -3.70 | P/E | N/A | Forward P/E | -19.02 |
| Beta | 2.19 | Short Ratio | 5.76 | Inst. Own | 88.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 40.56 | 200-d Avg | 27.87 | 1yr Est | 72.33 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-05 | 2026-09 | -0.56 | N/A | N/A | N/A |
| 2026-08-06 | 2026-06 | -0.54 | -1.44 | -0.9 | -166.16% |
| 2026-05-07 | 2026-03 | -0.47 | -0.71 | -0.24 | -51.06% |
| 2026-02-26 | 2025-12 | -0.48 | -0.51 | -0.03 | -5.44% |
| 2025-11-06 | 2025-09 | -0.52 | -0.78 | -0.26 | -50.00% |
| 2025-07-31 | 2025-06 | -0.38 | -0.5 | -0.12 | -31.58% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-10-09 | JP Morgan | Upgrade | Overweight | |
| 2026-09-15 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2026-09-15 | Baird | Upgrade | Outperform | Outperform |
| 2026-09-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-09-14 | Needham | Upgrade | Buy | Buy |
| 2026-09-11 | RBC Capital | Upgrade | Outperform | Outperform |
Profile
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-01-28 | Adsett (Roger) | Director of Issuer | 0.00 | Opening Balance-Initial SEDI Report |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Blackrock Inc. | 11.23M | 414.49M | 8.36% |
| 2026-06-29 | Avoro Capital Advisors LLC | 7.19M | 265.27M | 5.35% |
| 2026-06-29 | Driehaus Capital Management, LLC | 6.85M | 252.59M | 5.09% |
| 2026-06-29 | Jupiter Topco LLC | 5.62M | 207.22M | 4.18% |
| 2026-06-29 | Capital World Investors | 5.37M | 198.07M | 3.99% |
| 2026-06-29 | FMR, LLC | 4.75M | 175.38M | 3.54% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | SmallCap World Fund Inc | 7.69M | 283.72M | 5.72% |
| 2026-08-30 | iShares Trust-iShares Russell 2000 ETF | 3.33M | 123.03M | 2.48% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.49M | 54.86M | 1.11% |
| 2026-07-30 | Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.42M | 52.50M | 1.06% |
| 2026-06-29 | T. Rowe Price Health Sciences Fund, Inc. | 1.29M | 47.50M | 0.96% |
| 2026-08-30 | iShares Trust-iShares Russell 2000 Growth ETF | 1.22M | 45.20M | 0.91% |